Monday, March 16, 2026
Written By Param Malik, Editor-in-Chief
The "Grand Bargain" has moved into its second phase: the codified budget. As the White House unveils a 2027 request that trades deep agency cuts for massive insurer windfalls, the industry is recalibrating. We are watching the structural defunding of the old guard (NIH/HHS) in favor of a "pay-to-play" model driven by direct-to-consumer portals like LillyDirect.
The era of the "Administrative State" is receding; the era of the "Marketplace State" is here. Let’s dive in.
Let’s dive in.
Last Week in Biotech, Pharma & Finance
The 2027 Budget: The White House released its 2027 budget request, proposing a 12% cut to federal health agencies. The headline shocker? A $5 billion hit to the NIH. While Congress is unlikely to swallow these cuts whole, the message is clear: the administration wants to divert those funds toward the Administration for a Healthy America, the RFK Jr.-led agency that aims to bypass traditional HHS structures.
The $18.6 Billion Insurer Gift: In a massive win for payers, CMS released final regulations on Medicare Advantage Star Ratings. By slashing the number of quality and care measures plans are graded on, the feds are essentially funneling an extra $18.6 billion to insurers over the next decade. This is significantly more "payer-friendly" than the November proposal, suggesting the administration is prioritizing insurer stability over rigorous quality metrics.
100% Tariffs (With a Catch): President Trump announced 100% tariffs on brand-name drugs, but the "fine print" is where the story lives. The taxes won't apply to the major drugmakers who signed the MFN pricing deals or to key "Most Favored" trading partners. This turns the tariff from a trade tool into a compliance hammer: sign a pricing deal, or face a 100% tax at the border.
The Obesity Pill Duel: The FDA approved Eli Lilly’s Foundayo (orforglipron) last Wednesday, officially sparking the "Oral GLP-1 War."
Lilly’s Move: Foundayo is launching immediately via LillyDirect (cash-pay), with analysts projecting 5M+ prescriptions in 2026.
Novo’s Defense: Novo Nordisk is aggressively counter-messaging, claiming "significantly greater" weight loss for the Wegovy pill compared to Foundayo’s data.
Small Pharma's Seat at the Table: Seeing the writing on the wall, smaller drugmakers are now rushing to negotiate their own pricing deals with the White House. They are trading price concessions for "Tariff Immunity," effectively replicating the strategy used by the Top 20 last year.
The Investors' Plea: Biotech investor Rod Wong and a new industry-patient coalition sent a formal letter to the President. Their ask? More regulatory flexibility at the FDA, particularly for rare diseases, citing a "chilling effect" on investment following recent high-profile rejections.
New drugs approved by the FDA?
This Week: Yes.
Foundayo (orforglipron): Approved 4/1/2026. This is the first non-peptide, small-molecule oral GLP-1 for chronic weight management. Unlike Wegovy's oral version, Foundayo doesn't have the same strict fasting requirements, which could be its "X-factor" in patient adherence.
The Latest from Healthcare Insights
Here's what we're writing about at healthcarein.org:
What’s on Our Mind for the Next Two Weeks
This Week (April 6): The Two-Tiered FDA There is a growing divide between "National Priority" drugs (Obesity, Oncology) that are getting fast-tracked through direct deals, and "Standard" biotech R&D that is facing an increasingly skeptical, underfunded FDA. Are we moving toward a system where "political utility" determines clinical approval?
Next Week (April 13): The Small Pharma Squeeze As mid-cap and small-cap companies sign these "Voluntary" pricing deals to avoid 100% tariffs, we’ll be looking at their balance sheets. Unlike Big Pharma, small biotechs don't have the volume to offset 50%+ price cuts. We expect a wave of "forced M&A" as these companies realize they can't survive the new pricing reality alone.
The Week Ahead
April 7: World Health Day. Watch for a "Counter-WHO" statement from the Administration for a Healthy America regarding global pandemic treaty alternatives.
April 9: CMS Webinar on Star Ratings. Insurers will be listening for the technical details on how to claim that $18.6B.
April 10: Foundayo Shipments Begin. We will be tracking the initial "LillyDirect" wait times to gauge real-world demand.
Takeaways
This week marks the end of "uncertainty" and the beginning of "the bill." We now know the price of peace: drugmakers must invest domestically and cut prices to avoid 100% tariffs, while insurers are being compensated with $18B in regulatory relief to keep the system afloat. In the "Marketplace State," the winners are those who own the distribution (Lilly) or the network (UnitedHealth/Cigna).
Stay curious, stay sharp, and we will see you in seven days.
With gratitude and resolve,
The Healthcare Insights Team
Reach out to us by email at [email protected].
